Novel kynurenic acid analogues in the treatment of migraine and neurodegenerative disorders

Preclinical studies and pharmaceutical design

J. Tajti, Zsófia Majláth, Délia Szok, Anett Csáti, J. Toldi, F. Fülöp, L. Vécsei

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Though migraine and neurodegenerative disorders have a high socioeconomic impact, their therapeutic management has not been fully addressed. Their pathomechanisms are not completely understood, but glutamateinduced excitotoxicity, mitochondrial disturbances and oxidative stress all seem to play crucial roles. The overactivation of glutamate receptors contributes to the hyperexcitability observed in migraine and also to the neurodegenerative process. The kynurenine pathway of the tryptophan metabolism produces the only known endogenous Nmethyl-D-aspartate receptor antagonist, kynurenic acid, which has been proven in different preclinical studies toexert a neuroprotective effect. Influencing the kynurenine pathway might be beneficial in migraine and neurodegenerative diseases, and in the normalization of glutamatergic neurotransmission and the prevention of excitotoxic neuronal damage. Thesynthesis of kynurenic acid analogues may offer a valuable tool for drug development.

Original languageEnglish
Pages (from-to)2250-2258
Number of pages9
JournalCurrent Pharmaceutical Design
Volume21
Issue number17
Publication statusPublished - May 1 2015

Fingerprint

Kynurenic Acid
Migraine Disorders
Neurodegenerative Diseases
Kynurenine
Pharmaceutical Preparations
D-Aspartic Acid
Glutamate Receptors
Neuroprotective Agents
Synaptic Transmission
Tryptophan
Oxidative Stress
Therapeutics

Keywords

  • Hyperexcitability
  • Kynurenic acid
  • Kynurenic acid analogues
  • Migraine
  • Neurodegeneration
  • Neuroprotection

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Novel kynurenic acid analogues in the treatment of migraine and neurodegenerative disorders : Preclinical studies and pharmaceutical design. / Tajti, J.; Majláth, Zsófia; Szok, Délia; Csáti, Anett; Toldi, J.; Fülöp, F.; Vécsei, L.

In: Current Pharmaceutical Design, Vol. 21, No. 17, 01.05.2015, p. 2250-2258.

Research output: Contribution to journalArticle

@article{f1245c5322cc43c5baadebe4c26ae03a,
title = "Novel kynurenic acid analogues in the treatment of migraine and neurodegenerative disorders: Preclinical studies and pharmaceutical design",
abstract = "Though migraine and neurodegenerative disorders have a high socioeconomic impact, their therapeutic management has not been fully addressed. Their pathomechanisms are not completely understood, but glutamateinduced excitotoxicity, mitochondrial disturbances and oxidative stress all seem to play crucial roles. The overactivation of glutamate receptors contributes to the hyperexcitability observed in migraine and also to the neurodegenerative process. The kynurenine pathway of the tryptophan metabolism produces the only known endogenous Nmethyl-D-aspartate receptor antagonist, kynurenic acid, which has been proven in different preclinical studies toexert a neuroprotective effect. Influencing the kynurenine pathway might be beneficial in migraine and neurodegenerative diseases, and in the normalization of glutamatergic neurotransmission and the prevention of excitotoxic neuronal damage. Thesynthesis of kynurenic acid analogues may offer a valuable tool for drug development.",
keywords = "Hyperexcitability, Kynurenic acid, Kynurenic acid analogues, Migraine, Neurodegeneration, Neuroprotection",
author = "J. Tajti and Zs{\'o}fia Majl{\'a}th and D{\'e}lia Szok and Anett Cs{\'a}ti and J. Toldi and F. F{\"u}l{\"o}p and L. V{\'e}csei",
year = "2015",
month = "5",
day = "1",
language = "English",
volume = "21",
pages = "2250--2258",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "17",

}

TY - JOUR

T1 - Novel kynurenic acid analogues in the treatment of migraine and neurodegenerative disorders

T2 - Preclinical studies and pharmaceutical design

AU - Tajti, J.

AU - Majláth, Zsófia

AU - Szok, Délia

AU - Csáti, Anett

AU - Toldi, J.

AU - Fülöp, F.

AU - Vécsei, L.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Though migraine and neurodegenerative disorders have a high socioeconomic impact, their therapeutic management has not been fully addressed. Their pathomechanisms are not completely understood, but glutamateinduced excitotoxicity, mitochondrial disturbances and oxidative stress all seem to play crucial roles. The overactivation of glutamate receptors contributes to the hyperexcitability observed in migraine and also to the neurodegenerative process. The kynurenine pathway of the tryptophan metabolism produces the only known endogenous Nmethyl-D-aspartate receptor antagonist, kynurenic acid, which has been proven in different preclinical studies toexert a neuroprotective effect. Influencing the kynurenine pathway might be beneficial in migraine and neurodegenerative diseases, and in the normalization of glutamatergic neurotransmission and the prevention of excitotoxic neuronal damage. Thesynthesis of kynurenic acid analogues may offer a valuable tool for drug development.

AB - Though migraine and neurodegenerative disorders have a high socioeconomic impact, their therapeutic management has not been fully addressed. Their pathomechanisms are not completely understood, but glutamateinduced excitotoxicity, mitochondrial disturbances and oxidative stress all seem to play crucial roles. The overactivation of glutamate receptors contributes to the hyperexcitability observed in migraine and also to the neurodegenerative process. The kynurenine pathway of the tryptophan metabolism produces the only known endogenous Nmethyl-D-aspartate receptor antagonist, kynurenic acid, which has been proven in different preclinical studies toexert a neuroprotective effect. Influencing the kynurenine pathway might be beneficial in migraine and neurodegenerative diseases, and in the normalization of glutamatergic neurotransmission and the prevention of excitotoxic neuronal damage. Thesynthesis of kynurenic acid analogues may offer a valuable tool for drug development.

KW - Hyperexcitability

KW - Kynurenic acid

KW - Kynurenic acid analogues

KW - Migraine

KW - Neurodegeneration

KW - Neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=84929463833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929463833&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 2250

EP - 2258

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 17

ER -